Ty - jour t1 -呼吸2:第三阶段的环丙沙星的干粉吸入安慰剂对照随机试验non-cystic纤维化支气管扩张JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02053 -2017欧元六世- 51 - 1 SP - 1702053 AU Aksamit盖非盟- De Soyza安东尼盟——知识,Tiemo-Joerg AU -克里奥罗,玛格丽塔非盟- Elborn,j·斯图尔特盟——Operschall伊丽莎白AU - Polverino,伊娃AU -罗斯,凯特琳AU -温斯洛普,凯文·l . AU -威尔逊,罗伯特Y1 - 2018/01/01 UR - //www.qdcxjkg.com/content/51/1/1702053.abstract N2 -我们评估疗效和安全性的环丙沙星干粉吸入(DPI) non-cystic纤维化患者支气管扩张,前一年有两次或两次以上的病情加重，并有预先确定的痰菌。患者被随机分为2:1至每日两次的环丙沙星DPI 32.5 mg或安慰剂，治疗周期为14或28天，治疗周期为48周。主要终点是第一次发作的时间和发作的频率。纳入国家和α水平分裂(14天和28天周期分别为0.049和0.001)与RESPIRE 1不同。患者随机分为环丙沙星DPI组(14天开/关(n=176)或28天开/关(n=171)或安慰剂组(14天开/关(n=88)或28天开/关(n=86))。各治疗组的加重率较低(平均±sd 0.6±0.9)。积极治疗显示了延长第一次发作时间的趋势(环丙沙星DPI 14天开启/关闭:风险比0.87,95.1% CI 0.62-1.21; p=0.3965; ciprofloxacin DPI 28 days on/off: hazard ratio 0.71, 99.9% CI 0.39–1.27; p=0.0511) and reduced frequency of exacerbations (ciprofloxacin DPI 14 days on/off: incidence rate ratio 0.83, 95.1% CI 0.59–1.17; p=0.2862; ciprofloxacin DPI 28 days on/off: incidence rate ratio 0.55, 99.9% CI 0.30–1.02; p=0.0014), although neither achieved statistical significance. Ciprofloxacin DPI was well tolerated.Trends towards clinical benefit were seen with ciprofloxacin DPI, but primary end-points were not met.RESPIRE 2 supports ciprofloxacin DPI clinical benefits in bronchiectasis, but did not reach statistical significance http://ow.ly/es9E30gNhos ER -